China
Africa
Explore chapters and articles related to this topic
Assessment Screening Tools and Approaches
Published in Danielle L. Terry, Michelle E. Mlinac, Pamela L. Steadman-Wood, Providing Home Care for Older Adults, 2020
Courtney O. Ghormley, James “Chip” Long
If necessary, consider adjusting the assessment battery to compensate for the patient’s visual or hearing limitations. This could include scaling down a larger battery such as the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (Randolph, Tierney, Mohr, and Chase, 1998) so that items requiring vision are omitted for someone who has significant visual impairment. You can also consider using different tests developed for those with sensory impairment (i.e. MoCA-BLIND; Wittich, Phillips, Nasreddine, & Chertkow, 2010).
Health-related quality of life and palliative care issues in neurotrauma
Published in Hemanshu Prabhakar, Charu Mahajan, Indu Kapoor, Essentials of Anesthesia for Neurotrauma, 2018
Suparna Bharadwaj, Lashmi Venkatraghavan
Other QOL measures whose reliability and validity have been investigated in the context of TBI are Hardon’s scale, Schedule for the Evaluation of Individual Quality of Life—Direct Weighting, Hospital Anxiety and Depression scale, Repeatable Battery for the Assessment of Neuropsychological Status, Iowa–Netherlands Social Comparison Orientation Measure, Patient Competency Rating Scale, Multidimensional Scale of Perceived Social Support, Brief-COPE, and Life Orientation Test—Revised.
Contribution of the neuropsychological evaluation to traumatic brain injury rehabilitation
Published in Mark J. Ashley, David A. Hovda, Traumatic Brain Injury, 2017
A popular shorter neuropsychological battery is the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS Update),13 which has four forms of the test—now with downward extension to the age of 12—and is applicable to those up to age of 89. There is a Spanish form of this test battery. The RBANS covers Immediate Memory, Visuospatial/Constructional, Language, Attention, and Delayed Memory. Many clinicians will also augment the RBANS with measure of executive abilities and sensory–motor functions that are not explicitly covered in the examination. For older adults, the Kaplan-Baycrest Neurocognitive Assessment14 provides an option of a neuropsychological test battery that is standardized for this population.
Subjective executive dysfunction in patients with primary brain tumors and their informants: relationships with neurocognitive, psychological, and daily functioning
Published in Brain Injury, 2021
Sarah Ellen Braun, Autumn Lanoye, Farah J Aslanzadeh, Ashlee R Loughan
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (41) is a performance-based assessment of cognitive functioning composed of 12 subtests used to assess cognitive impairment across five domains: immediate memory, delayed memory, attention, language, and visuospatial-construction. The RBANS yields age-normed scores for each subtest and domain in addition to a total score based on a normal distribution curve (i.e., mean of 100 and standard deviation of 15). The RBANS is a well-validated tool (42) that has been used with patients with PBT in previous research (43,44). The RBANS has shown good sensitivity in identifying patients with dementia and characterizing unique cognitive profiles (45,46), it also shows clinical utility in identifying those with mild cognitive impairment from healthy controls (47,48). Further, it has four alternative forms to allow for retesting, making it clinically useful when tracking neurocognitive functions with serial testing and has been found to reliably predict cognitive change over time (49,50).
The Repeatable Battery for the Assessment of Neuropsychological Status as a screening strategy for HIV-Associated Neurocognitive Disorders
Published in AIDS Care, 2021
Diego Costaggiu, Elisa Pinna, Luca Serchisu, Doris Barcellona, Paola Piano, Francesco Ortu, Francesco Marongiu, Antonella Mandas
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is a widely used screening instrument in neuropsychological assessment (Duff et al., 2003, 2005; Ponteri et al., 2007; Randolph et al., 1998; Wilk et al., 2004). It consists of 12 subtests, most of which are similar to individual neuropsychological measures, but has the benefit of being brief and tolerable to complete as compared with other neuropsychological batteries, while providing more detailed information than many other screening measures (Randolph et al., 1998). The RBANS is still little used today as a cognitive screening tool in HIV-infected (Costaggiu et al., 2015), but the rationale for its use could reside in the current characteristics of HAND: in fact, the HAND phenotype appears to have switched from a subcortical disorder that predominantly affects memory and speed of cognitive processing to one that may have a mixed pattern of involvement with both subcortical and cortical involvement (McArthur et al., 2010).
Selective α7 nicotinic receptor agonists and positive allosteric modulators for the treatment of schizophrenia – a review
Published in Expert Opinion on Investigational Drugs, 2020
Kirsten Antonio-Tolentino, Corey R. Hopkins
A search of the clinical trials website (clinicaltrials.gov) came back with 12 studies on α7 nicotinic receptor modulators, with no open trials. The two compounds that have been evaluated over the past 5–6 years are shown in Figure 4. The first compound, EVP-6124 (also known as encenicline), is an α7 nicotinic receptor partial agonist. The Phase I PK study was reported in 2015 and showed that EVP-6124 was well tolerated and dose-proportional up to 180 mg dose (NCT01073228). In addition, time-dependent pharmacodynamic effects on the central nervous system were observed [13,42,43]. However, in 2016, Forum Pharmaceuticals reported that EVP-6124 had failed the main goal – the drug did not show statistically significant benefit on cognitive function in a Phase 3 study. In addition, the FDA placed a hold on two additional late-stage studies of EVP-6124 in Alzheimer’s disease due to gastrointestinal safety issues. The next compound that entered clinical trials is AVL-3288, which is an α7 nicotinic positive allosteric modulator (PAM). AVL-3288 was evaluated for efficacy in a Phase 1b, randomized, double-blind, placebo-controlled, triple cross-over study using two doses (10 and 30 mg) in patients with schizophrenia or schizoaffective disorder (BCT02878599). The primary outcome was the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total score – patients that were enrolled all had RBANS ≥ 62 [44]. The primary outcome for this study was negative and non-significant worsening for the active groups vs. placebo was also noted. Thus, the results did not show efficacy for the PAM compound, reflecting the results seen for the previous agonist compound [44].